Company profile: PDC Line Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage active cancer immunotherapies based on an allogeneic plasmacytoid dendritic cell line (PDC*line) loaded with cancer antigens, including PDC*lung01, a therapeutic vaccine for non-small cell lung cancer used with anti-PD-1 to induce specific immune responses, and GeniusVac-Mel4, a vaccine designed to prime and expand antitumor T-cells in melanoma patients.
Products and services
- PDC*line Allogeneic Plasmacytoid Dendritic Cell Line Platform: The proprietary plasmacytoid dendritic cell line is loaded with cancer antigens to create active immunotherapies for cancer that stimulate antitumor immunity
- PDC*lung01 Therapeutic Cancer Vaccine: A clinical-stage therapeutic cancer vaccine for non-small cell lung cancer, administered with anti-PD-1 therapy to induce specific immune responses
- GeniusVac-Mel4 Cancer Vaccine: A plasmacytoid dendritic cell line–based product engineered to prime and expand antitumor T-cells in melanoma patients.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PDC Line Pharma
Cytognos
HQ: Spain
Website
- Description: Provider of flow cytometry solutions for blood cancer diagnosis, minimal residual disease detection, and immune monitoring research. Offers Infinicyt software for multicolor data integration and analysis; EuroFlow 8-color antibody panels; OC515 dye; APC-C750 fluorochrome; and Next Generation Flow immunophenotyping protocols.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytognos company profile →
Propella Therapeutics
HQ: United States
Website
- Description: Provider of lymphatic-targeted oncology therapeutics and a lymphatic targeting drug delivery platform. Uses medicinal chemistry to adapt known actives with validated mechanisms for lymphatic delivery. Pipeline includes PRL-02 (abiraterone decanoate, intramuscular) for advanced prostate cancer, targeting the androgen receptor pathway by inhibiting CYP17, delivered via the lymphatic system to enhance efficacy and safety by bypassing the liver and reducing plasma exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propella Therapeutics company profile →
Theolytics
HQ: United Kingdom
Website
- Description: Provider of next-generation viral therapies, leveraging phenotypic screening platforms to discover targeted oncolytic adenoviral candidates suitable for intravenous delivery and optimized for specific patient populations. Offerings include THEO-260 for platinum-resistant ovarian cancer, THEO-310 for multiple myeloma, proprietary adenovirus libraries for oncology, gene therapy and infectious diseases, and bioselection/screening systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theolytics company profile →
Tilos Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics targeting key immunological pathways, with a focus on regulatory T cells and effector cell regulation; developing anti-LAP antibodies specific to the Latency Associated Peptide of TGF beta for cancer treatment. Founded in 2016 and based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilos Therapeutics company profile →
Kronos Bio
HQ: United States
Website
- Description: Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kronos Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PDC Line Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PDC Line Pharma
2.2 - Growth funds investing in similar companies to PDC Line Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PDC Line Pharma
4.2 - Public trading comparable groups for PDC Line Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →